RUNX1 antibody

Catalog No. ABIN2665355

This anti-RUNX1 antibody is a Mouse Monoclonal antibody detecting RUNX1 in FACS. Suitable for Human.

Quick Overview for RUNX1 antibody (ABIN2665355)

Target: RUNX1 (Runt-Related Transcription Factor 1 (RUNX1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This RUNX1 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: 1C5B16

Product Details anti-RUNX1 Antibody

Cross-Reactivity: Mouse (Murine), Human

Cross-Reactivity (Details): Human

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for RUNX1

Target: RUNX1 (Runt-Related Transcription Factor 1 (RUNX1))

Alternative Name: RUNX1

Background: RUNX1 belongs to the runt domain family of transcription factors and regulates target gene expression through forming a heterodimeric DNA-binding complex with CBFB. RUNX1 was first identified as a RUNX1-ETO fusion protein in acute myeloid leukaemia (AML) and is frequently mutated in AML and myelodysplastic syndrome due to chromosomal translocation. RUNX1-deficient mice fail to generate hematopoietic stem cells. RUNX1 regulates CD4 gene transcription during multiple stages of T cell development and represses the CD4 gene in CD4-CD8- (double negative) T cells. RUNX1 is also required for the differentiation of CD8+, Th17, and regulatory T cells. Impaired differentiation of megakaryocytes and decreased circulating platelet count was observed in the absence of RUNX1. These findings revealed that RUNX1 acts as a tumor suppressor for myeloid leukemia and is crucial for the development and terminal differentiation of several blood cell lineages.